AirSculpt Technologies (NASDAQ:AIRS) Issues Earnings Results

AirSculpt Technologies (NASDAQ:AIRS) issued its quarterly earnings data on Tuesday. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.06, FiscalAI reports. AirSculpt Technologies had a negative return on equity of 14.30% and a negative net margin of 11.41%.The firm had revenue of $33.44 million during the quarter, compared to the consensus estimate of $34.93 million.

AirSculpt Technologies Stock Up 3.7%

NASDAQ:AIRS traded up $0.10 on Tuesday, hitting $2.83. The stock had a trading volume of 1,303,721 shares, compared to its average volume of 5,849,357. AirSculpt Technologies has a 1 year low of $1.51 and a 1 year high of $12.00. The firm’s fifty day simple moving average is $2.33 and its two-hundred day simple moving average is $4.40. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.51 and a current ratio of 0.51. The stock has a market cap of $176.71 million, a P/E ratio of -9.43 and a beta of 2.75.

Insider Buying and Selling at AirSculpt Technologies

In other AirSculpt Technologies news, major shareholder Jorey Chernett bought 105,848 shares of AirSculpt Technologies stock in a transaction dated Monday, March 16th. The stock was bought at an average cost of $2.43 per share, with a total value of $257,210.64. Following the completion of the acquisition, the insider directly owned 6,592,059 shares in the company, valued at approximately $16,018,703.37. The trade was a 1.63% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders purchased 600,150 shares of company stock valued at $1,404,424. 76.58% of the stock is owned by insiders.

Institutional Trading of AirSculpt Technologies

A number of large investors have recently bought and sold shares of AIRS. Virtu Financial LLC bought a new stake in shares of AirSculpt Technologies in the fourth quarter valued at $30,000. Millennium Management LLC purchased a new stake in AirSculpt Technologies in the 4th quarter worth about $33,000. Aigen Investment Management LP purchased a new stake in AirSculpt Technologies in the 4th quarter worth about $36,000. Wells Fargo & Company MN raised its stake in AirSculpt Technologies by 49.9% in the 4th quarter. Wells Fargo & Company MN now owns 19,275 shares of the company’s stock valued at $38,000 after acquiring an additional 6,420 shares during the period. Finally, BNP Paribas Financial Markets raised its stake in AirSculpt Technologies by 239.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,952 shares of the company’s stock valued at $48,000 after acquiring an additional 4,199 shares during the period. 91.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently issued reports on AIRS shares. Wall Street Zen downgraded AirSculpt Technologies from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of AirSculpt Technologies in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Reduce” and a consensus target price of $6.00.

About AirSculpt Technologies

AirSculpt Technologies, Inc (NASDAQ: AIRS) is a medical technology company specializing in minimally invasive body contouring. The company’s flagship AirSculpt® platform combines pneumatic power with precision microcannulas to deliver fat removal, transfer and sculpting procedures. AirSculpt Technologies partners with both company-owned and franchised cosmetic surgery practices to offer a streamlined, office-based alternative to traditional liposuction.

Through its proprietary system, AirSculpt Technologies provides both consumers and medical professionals with an integrated solution that emphasizes reduced downtime, smaller incision sites, and more predictable outcomes.